Oncolytics Biotech Inc.
Presenter: Brad Thompson, President and Chief Executive Officer
Company Information
Company Type: Therapeutics
Development Stage: Public
Company Profile
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN®, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
Company Strategy
Oncolytics Biotech® Inc. is conducting clinical trials in the U.S. and the U.K. with the objective of developing REOLYSIN® as a human cancer therapeutic. The current clinical program includes multiple Phase I/II and Phase II human trials examining REOLYSIN alone or in combination with chemotherapy. This clinical program is designed to identify targets for late-stage registration trials with REOLYSIN, the first of which is a Phase III combination REOLYSIN and paclitaxel/carboplatin trial for patients with platinum-failed head and neck cancers.
Intellectual Property
Oncolytics has secured more than 200 patents worldwide, including 33 issued U.S. patents, numerous additional U.S. patent applications and corresponding international patents and patent applications that protect REOLYSIN®, its medical use, combination therapies, manufacturing and other areas.
Management Team
Brad Thompson, Ph.D.
Chairman, President and Chief Executive Officer
Doug Ball, C.A.
Chief Financial Officer
Matt Coffey, Ph.D.
Chief Operating Officer
George Gill, M.D.
Senior Vice President, Clinical and Regulatory Affairs
Mary Ann Dillahunty, J.D., M.B.A.
Vice President, Intellectual Property
Presenter Bio
Dr. Brad Thompson has provided leadership to various organizations within the biotechnology sector for more than 20 years. He received his Ph.D. from the University of Western Ontario in the Department of Microbiology and Immunology, and is the current Chairman of the Board of BIOTECanada.
Contact
Oncolytics Biotech Inc.
210, 1167 Kensington Crescent NW
Calgary
AB , Canada
T2N 1X7
ph: 403.670.7377
fx: 403.283.0858
www.oncolytics.com
notan@aol.com